Thus, future studies exploring the tolerability and efficacy profile in specific disease subgroups, in addition or not to other drugs enhancing the D-amino acid pathway, will shed light on the real potential of DAO inhibitors in schizophrenia and other psychotic disorders. This evidence concerns the gene DAO and psychotic disorder.